Premium
P2‐187: Tau hyperphosphorylation in Alzheimer's disease: Systematic quantification of common disease‐relevant phospho‐sites
Author(s) -
Havas Daniel,
Kerschbaumer Bianca,
Attems Johannes,
Hutter Heinz,
Hutter-Paier Birgit,
Schweinzer Cornelia
Publication year - 2015
Publication title -
alzheimer's and dementia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.713
H-Index - 118
eISSN - 1552-5279
pISSN - 1552-5260
DOI - 10.1016/j.jalz.2015.06.726
Subject(s) - senile plaques , hyperphosphorylation , entorhinal cortex , tauopathy , tau protein , hippocampus , hippocampal formation , alzheimer's disease , neuroscience , pathological , dementia , pathology , disease , neurodegeneration , psychology , phosphorylation , biology , medicine , microbiology and biotechnology
Hippocampal pThr231 Tau increase is the earliest measurable event with the used set of markers. However, analyses of further potentially early stage C-terminal Tau markers are still outstanding and will be accomplished in future experiments. Figure 4. Graphs present stained or IR surface area at different stages of AD (A) ThioS positive tangles. (B) pTyr18 Tau load. (C) pSer202/Thr205 Tau load. (D) pThr231 Tau load. (E) pSer262 Tau load. (F) total human Tau load. Note that all measurements show a very clear increase between middle (III/IV) and end stage (V/VI). This is especially true for cortical regions, in which Tau hyperphosphorylation does not seem to play a major role before end stage. A small but insignificant increase at stage III/IV is detectable for ThioS tangles, only. Differently in the hippocampus, where at least two p-sites (pTyr18 and pThr231) are already significantly enhanced at stage III/IV, whereas the pThr231 Tau load is approximately double as high as pTyr18. Last but not least the quantification of pSer262 Tau did not reveal significant differences. The increase seen at stage V/VI was triggered by only one subject with high load. Statistical significance is indicated by One-Way ANOVA (Bonferroni’s Multiple Comparison Test). Data are shown as group mean + SEM. # significant versus all other groups; ‡ significant versus control group; + significant versus control group and I/II Antibody Clone [c] Dilution Producer Item No.